Dissolution enhancement of indomethacin via amorphization using co-milling and supercritical co-precipitation processing

Powder Technology

Volumn 240, Issue , 2013, Pages 79-87

  Lim, Ron Tau Yee ^a,b   Ng, Wai Kiong ^a   Tan, Reginald B H ^a,b  

^a INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Amorphization; Anti solvent; Co milling; Indomethacin; Physical stability; Supercritical fluid

Indexed keywords

ANTI-SOLVENTS; CO-MILLING; CO-PRECIPITATION PROCESSING; INDOMETHACIN; PHYSICAL STABILITY; POORLY WATER-SOLUBLE DRUGS; SUPERCRITICAL ANTISOLVENTS; X-RAY POWDER DIFFRACTOMETRY;

AMORPHIZATION; ASSOCIATION REACTIONS; CRYSTALLIZATION KINETICS; DIFFERENTIAL SCANNING CALORIMETRY; EFFLUENT TREATMENT; FOURIER TRANSFORM INFRARED SPECTROSCOPY; MILLING (MACHINING); POWDERS; SCANNING ELECTRON MICROSCOPY; SOLVENTS; SUPERCRITICAL FLUIDS; THERMOGRAVIMETRIC ANALYSIS;

DISSOLUTION;

INDOMETACIN; POLYMER; POVIDONE;

AMORPHIZATION; ARTICLE; CHEMICAL COMPOSITION; CHEMICAL INTERACTION; CO MILLING; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG SOLUBILITY; DRUG STABILITY; INFRARED SPECTROSCOPY; PHARMACOLOGICAL PARAMETERS; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SUPERCRITICAL CO PRECIPITATION PROCESSING; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION;

EID: 84887007984     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2012.07.004     Document Type: Article

References (58)

1. Sharma P., Denny W.A., Garg S. Effect of wet milling process on the solid state of indomethacin and simvastatin. International Journal of Pharmaceutics 2009, 380:40-48.
2. Chawla G., Gupta P., Thilagavathi R., Chakraborti A.K., Bansal A.K. Characterization of solid-state forms of celecoxib. European Journal of Pharmaceutical Sciences 2003, 20:305-317.
3. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Advanced Drug Delivery Review 2001, 48:27-42.
4. Chadha R., Kashid N., Jain D.V.S. Characterization and quantification of amorphous content in some selected parenteral cephalosporins by calorinetric method. Journal of Thermal Analysis and Calorimetry 2005, 81:277-284.
5. Craig D.Q.M., Royall P.G., Kett V.L., Hopton M.L. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. International Journal of Pharmaceutics 1999, 179:179-207.
6. g drug. Powder Technology 2006, 167:20-25.
7. Watanabe T., Hasegawa S., Wakiyama N., Kusai A., Senna M. Comparison between polyvinylpyrrolidone and silica nanopariticles as carriers for indomethacin in a solid state dispersion. International Journal of Pharmaceutics 2003, 2003:250-283.
8. Balani P.N., Wong S.Y., Ng W.K., Tan R.B.H., Chan S.Y. Influence of polymer content on stabilizing milled amorphous salbutamol sulphate. International Journal of Pharmaceutics 2010, 391:125-136.
9. Lim R.T.Y., Ng W.K., Tan R.B.H. Amorphization of pharmaceutical compound by co-precipitation using supercritical anti-solvent (SAS) process (part I). Journal of Supercritical Fluids 2010, 53:179-184.
10. Takeuchi H., Nagira S., Yamamoto H., Kawashima Y. Solid dispersion particles of tolbutamide prepared by fine silica particles by spray dried method. Powder Technology 2004, 141:187-195.
11. Yang K.Y., Glemza R., Jarowski C.I. Effects of amorphous silicon dioxides on drug dissolution. Journal of Pharmaceutical Sciences 1979, 68:560-565.
12. Deepak B., Bogner H. Amorphization of indomethacin by co-grinding with neusilin US2: amorphization kinetics, physical stability and mechanism. Pharmaceutical Research 2006, 23:2317-2325.
13. Balani P.N., Ng W.K., Tan R.B.H., Chan S.Y. Influence of excipients in comiling on mitigating millied-induced amorphization or structural disorder of crystalline pharmaceutical actives. Journal of Pharmceutical Sciences 2009, 99:2462-2474.
14. Yusuke S., Makiko F., Yuka S., Ryusuke Y., Shinji F., Sayaka N., et al. The preparation of solid dispersion powder of indomethacin with crospovidone using a twin-screw extruder or kneader. International Journal of Pharmaceutics 2009, 365:53-60.
15. Breitenbach J. Melt extrusion: from process to drug delivery technology. European Journal of Pharmaceutics and Biopharmaceutics 2002, 54:107-117.
16. Yonemochi E., Kitahara S., Maeda S., Yamamura S., Oguchi T., Yamamoto K. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. European Journal of Pharmaceutical Sciences 1999, 7:331-338.
17. Usui F., Ikeda M., Isobe T., Senna M. Stability of amorphous indomethacin compounded with silica. International Journal of Pharmaceutics 2001, 226:81-91.
18. Majerik V., Horv'ath G., Charbit G., Badens E., Szokonya L., Bosc N., et al. Novel particle engineering techniques in drug delivery: review of formulations using supercritical fluids and liquefied gases. Hungarian Journal of Industrial Chemistry 2004, 32:41-56.
19. Majerik V., Charbit G., Badens E., Horv'ath G. Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. Journal of Supercritical Fluids 2007, 40:101-110.
20. Fages J., Lochard H., Letourneau J.J., Sauceau M., Rodier E. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technology 2004, 141:219-226.
21. Jung J., Perrut M. Particle design using supercritical fluids: literature and patent survey. Journal of Supercritical Fluids 2001, 20:179-219.
22. Surana R., Pyne A., Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharmaceutical Research 2004, 21:1167-1176.
23. Crowley K.J., Zografi G. Cryogenic milling of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. Journal of Pharmceutical Sciences 2002, 91:779.
24. Shaktshneider T.P. Phase transformations and stabilization of metastable states of molecular crystals under mechanical activation. Solid State Ionics 1997, 101-103:851-856.
25. Dudognon E., Willart J.F., Caron V., Capet F., Larsson T., Decamps M. Formations of budesonide/alpha-lactose glass solutions by ball-milling. Solid State Communications 2006, 138:68-71.
26. Font J., Muntasell J., Cesari E. Amorphization of organic compounds by ball-milling. Material Research Bulletin 1997, 32:1691-1696.
27. Bailey A.G. Electrostatic phenomena during powder handling. Powder Technology 1984, 37:71-85.
28. Atkinson M.B.J., Bucar D.K., Sokolov A.N., Friscic T., Robinson C.N., Bilal M.Y., et al. General application of mechanochemistry to templated solid-state reactivity: rapid and solvent-free access to crystalline supermolecules. Chemical Communications 2008, 396:83-90.
29. g. Journal of Pharmceutical Sciences 2007, 96:1398-1407.
30. Barzegar-Jalali M., Valizadeh H., Shadbad M.R., Adibkia K., Mohammadi G., Fara-hani A., Arash Z., Nokhodchi A. Cogrinding as an approach to enhance dissolution rate of a poorly water-soluble drug (gliclazide). Powder Technology 2010, 197:150-158.
31. Colombo I., Grassi G., Grassi M. Drug mechanochemical activation. Journal of Pharmceutical Sciences 2009, 98:3961-3986.
32. Bahl D., Hudak J., Bogner R.H. Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. Pharmaceutical Development and Technology 2008, 13:255-269.
33. Perrut M., Jung J., Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluids process, part 1: micronization of neat particles. International Journal of Pharmaceutics 2005, 288:3-10.
34. Subramaniam B. Pharmaceutical processing with supercritical carbon dioxide. Journal of Pharmceutical Sciences August 8 1997, 86(8).
35. Sethia S., Squillante E. Solid dispersion of carbamazepine in PVPK30 by conventional solvent evaporation and supercritical methods. International Journal of Pharmaceutics 2004, 272:1-10.
36. Gong K., Viboonkiat R., Rehman I.U., Buckton G., Darr J.A. Formation and characterization of porous indomethacin-PVP coprecipitates prepared using solvent-free supercritical fluid processing. Journal of Pharmaceutical Sciences 2005, 60:2583-2590.
37. Mauro B., Luigi M., Silvia R., Pasquale C., Ada F. Supercritical solvent impregnation of piroxicam on PVP at various polymer weight. Journal of Supercritical Fluids 2009, 49:271-278.
38. 2 anti-solvent precipitation. Journal of Supercritical Fluids 2009, 48:176-182.
39. Al Shaal L., Müller R.H., Shegokar R. Smart crystal combination technology-scale up from lab to pilot scale and long term stability. Pharmazie 2010, 65:877-884.
40. Stein J., Fuchs T., Mattern C. Advanced milling and containment technologies for superfine active pharmaceutical ingredients. Chemical Engineering and Technology 2010, 33:1464-1470.
41. Shoyele S.A., Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Advanced Drug Delivery Reviews 2006, 58:1009-1029.
42. Yasuji T., Takeuchi H., Kawashima Y. Particle design of poorly water-soluble drug substances using supercritical fluid technologies. Advanced Drug Delivery Reviews 2008, 60:388-398.
43. 2: a green solvent. Chemical Engineering 2010, 117:15-18.
44. Andronis V., Zografi G. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. Journal of Non-Crystalline Solids 2000, 271:236-248.
45. Takehiro O., Masaya I., Kozo T., Makoto O. Polymorphic transformation of indomethacin under high pressures. Journal of Pharmceutical Sciences 2005, 95:689-700.
46. Parrott G.L. Milling of pharmaceutical solids. Journal of Pharmceutical Sciences 1974, 63:813-829.
47. Gupta M.K., Vanwert A., Bogner R.H. Formation of physically stable amorphous drugs by milling with neusilin. Journal of Pharmceutical Sciences 2003, 93:536-551.
48. Aceves-Hernandez J.M., Nicolas-Vazquez I., Aceves F.J., Hinojosa-Torres J., Paz M., Castano V.M. Indomethacin polymorphs: experimental and conformational analysis. Journal of Pharmaceutical Sciences 2009, 98:2448-2463.
49. Uzun I.N., Sipahigil O., Dincer S. Co-precipitation of cefuroxime axetil-PVP composite microparticles by batch supercritical antisolvent process. Journal of Supercritical Fluids 2011, 55:1059-1069.
50. Lee K.R., Kim E.J., Seo S.W., Choi H.K. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine. Archives of Pharmacal Research 2008, 31:1023-1028.
51. Mura P., Cirri M., Faucci M.T., Gines-Dorado J.M., Bettinetti G.P. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. Journal of Pharmaceutical and Biomedical Analysis 2002, 30:227-237.
52. Park J.H., Yan Y.D., Chi S.C., Hwang D.H., Shanmugam S., Lyoo W.S., et al. Preparation and evaluation of cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process. Pharmacy and Pharmacology 2011, 63:491-499.
53. Patterson J.E., James M.B., Forster A.H., Lancaster R.W., Butler J.M., Rades T. The influence of thermal and mechanical preparative techniques on amorphous state of four poorly soluble compound. Journal of Pharmaceutical Sciences 2005, 94:1998-2012.
54. Chieng N., Aaltonen J., Saville D., Rades T. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. European Journal of Pharmaceutics and Biopharmaceutics 2009, 71:47-54.
55. Paes S.S., Sun S., MacNaugtan W., Ibbett R., Ganster J., Foster T.J., et al. The glass transition and crystallization of ball milled cellulose. Cellulose 2010, 17:693-709.
56. Fukuoka E., Markita M., Yamamura S. Some physicochemical properties of glassy indomethacin. Chemical & Pharmaceutical Bulletin 1986, 34:4314-4321.
57. Silverstein R.M., Bassler G.C., Morril T.C. Spectrometric Identification of Organic Compounds 1991, Wiley, New York.
58. Gordon M., Taylor J.S. Ideal copolymers and the second-order transition of synthetic rubbers 1. Non-crystalline co-polymers. Journal of Applied Chemistry 1952, 2:493-500.